Given Imaging Hosts 2nd Annual Conference on Capsule Endoscopy in Berlin

Global GI Specialists Gather To Share Clinical Experiences

3/14/2003 - Yoqneam, Israel - Given Imaging Ltd. (NASDAQ: GIVN) announced today that gastrointestinal specialists from around the world will meet in Berlin, Germany from March 23rd - 25th to share their experience with capsule endoscopy and how it is changing clinical practice at the Second Capsule Endoscopy Conference. The European Society of Gastrointestinal Endoscopy (ESGE) has applied for CME accreditation (12 points), which has already been granted in Germany, and submitted to the United European Medical Specialists (UEMS) Organization for European and American CME issuance.

Scientific sessions will focus on specific disease states including inflammatory bowel disease, celiac disease, obscure bleeding, small bowel pathology, small bowel neoplasia as well as on emerging areas such as pediatric use of capsule endoscopy. Participants will also be able to share experiences and ideas on how to improve examination and reviewing techniques. Over 90 abstracts and posters will be presented by 80 physicians from 23 countries around the world.

"This forum enables gastroenterologists to learn about emerging clinical practice related to capsule endoscopy and affords us the opportunity to share our own experiences with the M2A with colleagues from around the world," said Dr. Javier P. Piqueras, president-elect of the United European Gastroenterology Week Congress 2003.

"We are encouraged by the enthusiastic response that we have received about this our second Capsule Endoscopy conference. With over 30,000 capsules ingested to date, these gastroenterologists have gained substantial experience in using the M2A to treat patients with difficult-to-diagnose gastrointestinal disorders and we look forward to learning from them," said Gavriel D. Meron, President and CEO of Given Imaging Ltd.

This press release contains forward-looking statements about Given Imaging, including projections about our business, our future revenues, and our future profitability, within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. For example, statements in the future tense, words such as "anticipates," "estimates," "expects," "intends," "plans," "believes," and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify such forward-looking statements. Those forward-looking statements are not guarantees of future performance and actual results could differ materially from our current expectations as a result of numerous factors, including but not limited to the following: changes in regulatory environment, our success in implementing our sales, marketing and manufacturing plan, protection and validity of patents and other intellectual property rights, the impact of currency exchange rates, the effect of competition by other companies, the outcome of future litigation, the reimbursement policies for our product from healthcare payors, quarterly variations in operating results, the possibility of armed conflict or civil or military unrest in Israel and other risks disclosed in our filings with the U.S. Securities Exchange Commission.

19.Sept.'03